Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 218

Related Citations for PubMed (Select 21373851)

1.

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy.

Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K.

J Gastroenterol. 2011 Jun;46(6):799-808. doi: 10.1007/s00535-011-0384-z. Epub 2011 Mar 4.

PMID:
21373851
3.
4.

Analysis of hepatocellular carcinoma tumor growth detected in sustained responders to interferon in patients with chronic hepatitis C.

Toyoda H, Kumada T, Honda T, Hayashi K, Katano Y, Nakano I, Hayakawa T, Fukuda Y.

J Gastroenterol Hepatol. 2001 Oct;16(10):1131-7.

PMID:
11686840
5.

Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.

Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura S, Ohnishi H, Kuwaki K, Toshimori J, Hagihara H, Nouso K, Yamamoto K.

Dig Dis Sci. 2012 Apr;57(4):1092-101. doi: 10.1007/s10620-011-1934-1. Epub 2011 Oct 12.

PMID:
21989822
6.

Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, Kanda T, Kashiwagi T, Inoue A, Kato M, Oshima A, Kinoshita Y, Kamada T.

Int J Cancer. 2000 Sep 1;87(5):741-9.

PMID:
10925370
7.

Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.

Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.

J Gastroenterol Hepatol. 2005 May;20(5):752-8.

PMID:
15853990
8.

Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C.

Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T, Nakano S, Hayashi K, Katano Y, Nakano I, Hayakawa T, Nishimura D, Kato K, Imada K, Imoto M, Fukuda Y; Yon-Ken HCV-HCC Follow-up Study Group.

J Viral Hepat. 2000 Nov;7(6):414-9.

PMID:
11115052
9.

Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis.

Nagaoki Y, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Tsuge M, Hiramatsu A, Imamura M, Hyogo H, Kawakami Y, Takahashi S, Ochi H, Chayama K.

J Gastroenterol. 2013 Jul;48(7):847-55. doi: 10.1007/s00535-012-0679-8. Epub 2012 Oct 5.

PMID:
23053422
10.

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.

J Med Virol. 2007 Oct;79(10):1485-90.

PMID:
17705189
11.

Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C.

Takahashi H, Mizuta T, Eguchi Y, Kawaguchi Y, Kuwashiro T, Oeda S, Isoda H, Oza N, Iwane S, Izumi K, Anzai K, Ozaki I, Fujimoto K.

J Gastroenterol. 2011 Jun;46(6):790-8. doi: 10.1007/s00535-011-0381-2. Epub 2011 Feb 18.

PMID:
21331763
12.
13.

Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.

Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, Watanabe H.

J Gastroenterol. 2005 Feb;40(2):148-56.

PMID:
15770398
14.

Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.

Omata M, Yoshida H, Shiratori Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S141-3. Review.

PMID:
16234063
15.

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.

Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, Sakaguchi H, Kuroda T, Kioka K, Kim SR, Kanno T, Ueda T, Hirano M, Fujimoto S, Jomura H, Nishiguchi S, Seki S.

Liver Int. 2007 Mar;27(2):186-91.

PMID:
17311612
17.

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2011 Jun;83(6):1016-22. doi: 10.1002/jmv.22094.

PMID:
21503914
18.
19.

Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.

Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y.

Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S89-91.

PMID:
16234069
20.

Long-term responders without eradication of hepatitis C virus after interferon therapy: characterization of clinical profiles and incidence of hepatocellular carcinoma.

Yabuuchi I, Imai Y, Kawata S, Tamura S, Noda S, Inada M, Maeda Y, Shirai Y, Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y, Nishikawa M, Seki K, Matsuzawa Y.

Liver. 2000 Jul;20(4):290-5.

PMID:
10959807
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk